Atrium Therapeutics Q3FY26 Results: Net loss widens to $4.3 million
Atrium Therapeutics reported a Q3FY26 net loss of $4.3 million, which significantly beat analyst expectations, with an EPS of $(0.25) against an estimated $(1.37). Collaboration revenue surged 22.8% year-over-year to $15.3 million, largely due to a milestone payment from Bristol Myers Squibb. The company's cash runway now extends through 2028, bolstered by a $293.6 million pro-forma cash balance, as operating expenses rose to $22.0 million with increased clinical trial and administrative costs.
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
Atrium Therapeutics reported its financial results for the third quarter of 2026, highlighting significant progress in its precision cardiology pipeline. Key achievements include dosing the first patient in the Corventis™ Phase 1/2 clinical trial for PRKAG2 syndrome and presenting nonclinical data demonstrating ATR 1072's ability to reverse cardiac glycogen accumulation. The company also secured a $50 million private placement, extending its cash runway through 2028, and plans to file an IND for ATR 1086 in PLN cardiomyopathy in 2027.
Atrium Therapeutics, Inc. (RNA) stock price, news, quote and history
Atrium Therapeutics, Inc. (RNA) focuses on developing RNA therapeutics for cardiomyopathies, with lead candidates ATR 1072 and ATR 1086. The company, incorporated in 2025 and headquartered in San Diego, has collaborations with Bristol-Myers Squibb and Eli Lilly. Its stock performance shows a YTD return of 41.36%, and analysts have an average price target of $22.00, with a recent "Buy" rating maintained by HC Wainwright & Co.
Form 8K Atrium Therapeutics Inc For: 2 November By Investing.com
This article from Investing.com announces the filing of a Form 8K by Atrium Therapeutics Inc. for November 2nd. The content is brief, primarily serving as a notice of the regulatory filing.
Form 8K Atrium Therapeutics Inc For: 2 November By Investing.com
Investing.com reported on an 8K filing from Atrium Therapeutics Inc. for November 2nd. The article itself is very brief, simply stating the fact of the filing and its date, with no further details about the content of the 8K. The article was published on Investing.com's stock markets section.
Atrium Therapeutics to present PRKAG2 nonclinical data at AHA 2026
Atrium Therapeutics announced it will present nonclinical data for its investigational therapy ATR 1072 at the American Heart Association Scientific Sessions 2026. The data, generated in a mouse model of PRKAG2 syndrome, showed reversal of cardiac glycogen accumulation and improvement in hypertrophy and ECG parameters. The company expects initial proof-of-concept data from its Phase 1/2 Corventis trial in the second half of 2027 for this rare cardiomyopathy with no approved therapies.
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Atrium Therapeutics will present new nonclinical data at the AHA Scientific Sessions 2026, demonstrating that its investigational therapy, ATR 1072, reversed cardiac glycogen accumulation and improved other key features of PRKAG2 syndrome in a mouse model. These findings reinforce the scientific rationale for ATR 1072, which targets the root cause of the rare, early-onset cardiomyopathy. The company anticipates initial proof-of-concept data from its ongoing Phase 1/2 Corventis trial in the second half of 2027.
Form 8K Atrium Therapeutics Inc For: 2 November By Investing.com
Atrium Therapeutics Inc. filed a Form 8K for November 2nd, as reported by Investing.com. The article briefly mentions this filing and notes that the company's RNA stock is up 3.39%. This regulatory filing provides important information about significant events at the company.
H.C. Wainwright Maintains Atrium Therapeutics(RNA.US) With Buy Rating, Cuts Target Price to $20
H.C. Wainwright has reiterated its Buy rating on Atrium Therapeutics (RNA.US) but has adjusted its target price downwards to $20. This indicates continued confidence in the company's prospects despite a revised valuation.
HC Wainwright & Co. maintains Buy rating on Atrium Therapeutics, $20 price target
HC Wainwright & Co. has reiterated its Buy rating for Atrium Therapeutics, setting a price target of $20.00, which suggests a 140.4% upside from its previous close. This positive outlook is driven by the company's progress in clinical trials, particularly the Corventis study for ATR 1072, and strong financial backing providing a cash runway until 2028. These factors support investor confidence in Atrium Therapeutics' potential in RNA-based therapeutics.
Atrium Therapeutics Doses First Patient in ATR-1072 Trial for PRKAG2 Syndrome
Atrium Therapeutics has dosed its first patient in the Corventis Phase 1/2 trial for ATR-1072, a small interfering RNA therapy targeting PRKAG2 syndrome. This rare cardiac disease currently relies on symptomatic management, but ATR-1072 is designed to address the underlying genetic cause by silencing mutant PRKAG2 mRNA. The trial aims to determine if the therapy can normalize the gene defect in the heart, with interim data focusing on measurable reductions in cardiac PRKAG2 mRNA.
A rare heart condition’s first trial tests a treatment aimed at its genetic cause
Atrium Therapeutics has dosed the first patient in its Phase 1/2 Corventis clinical trial, evaluating ATR 1072 for PRKAG2 syndrome, a rare genetic heart muscle disease. This marks the first interventional trial for the condition, aiming to address the underlying genetic cause rather than just symptoms. The company anticipates reporting initial proof-of-concept data in the second half of 2027.
Form 8K Atrium Therapeutics Inc For: 27 October By Investing.com
This article from Investing.com announces the filing of a Form 8K by Atrium Therapeutics Inc. on October 27. The brief report indicates this financial filing is available for review, with no further details provided within the article itself.
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Atrium Therapeutics has dosed the first patient in its Phase 1/2 Corventis clinical trial for ATR 1072, an investigational therapy for PRKAG2 syndrome. This marks the first interventional trial for this rare genetic cardiomyopathy, which currently has no approved therapies. The company anticipates releasing initial proof-of-concept data in the second half of 2027.
Atrium Therapeutics doses first patient in PRKAG2 syndrome trial
Atrium Therapeutics has dosed the first patient in its Phase 1/2 Corventis clinical trial for ATR 1072, an investigational therapy for PRKAG2 syndrome, a rare genetic heart condition with no approved treatments. The trial aims to assess the safety and efficacy of ATR 1072, an antibody oligonucleotide conjugate designed to silence mutant PRKAG2 messenger RNA. Initial proof-of-concept data is expected in the second half of 2027.
Form 8K Atrium Therapeutics Inc For: 27 October By Investing.com
Investing.com reports that Atrium Therapeutics Inc. filed a Form 8K on October 27, 2026. The article is a brief announcement of this filing, typical for financial news platforms that track regulatory submissions. It includes no further details about the content of the 8K filing.
Atrium Therapeutics, Inc. Estimates – NASDAQ:RNA
This article provides an overview of Atrium Therapeutics, Inc. (NASDAQ:RNA) financial estimates on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates and visualization of trends over time.
Atrium Therapeutics is a buy, this analyst says
Roth Capital Partners analyst Boobalan Pachaiyappan initiated coverage of Atrium Therapeutics (NASDAQ:RNA) with a "Buy" rating and US$15.00 target, citing the company's potential to develop RNA-based treatments for rare genetic heart diseases. Despite a sharp decline in shares due to disappointing results from a related company, Pachaiyappan believes investors are misinterpreting Atrium's technology, which targets messenger RNA in the cell's cytoplasm. The company's strong cash position and two lead candidates, ATR1072 and ATR1086, targeting PRKAG2 syndrome and PLN cardiomyopathy respectively, provide significant commercial potential with unrisked peak worldwide sales projections reaching into the billions.
Roth/MKM initiates Atrium Therapeutics stock with buy rating By Investing.com
Roth/MKM has initiated coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and a $15.00 price target, highlighting the company's focus on cardiac-RNA therapies for rare cardiomyopathies. The firm notes that Atrium's stock is trading approximately 30% below its estimated pro forma cash per share and identifies a significant total addressable market for its pipeline drugs, ATR1072 and ATR1086. Cantor Fitzgerald also recently reiterated an Overweight rating with a $25.00 price target, projecting the company's cash runway through 2028 after a $50 million private placement.
Roth/MKM initiates Atrium Therapeutics stock with buy rating
Roth/MKM has initiated coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and a $15.00 price target, highlighting the company's focus on cardiac-RNA franchises for rare cardiomyopathies. The firm notes that Atrium's stock trades approximately 30% below its estimated pro forma cash per share, and the company's pipeline includes treatments for PRKAG2 syndrome and PLN cardiomyopathy, for which no current therapies exist. This positive outlook is further supported by a recent $50 million private placement that extends Atrium Therapeutics' cash runway through 2028.
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History
Atrium Therapeutics, Inc. (RNA) is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies, with current product candidates including ATR 1072 and ATR 1086. The company was incorporated in 2025 and is headquartered in San Diego, California. As of October 22, 2026, its stock price was $8.16, showing a 2.00% increase at close, with a reported year-to-date return of 44.03%.
Atrium Therapeutics, Inc. (RNA) stock price, news, quote and history
Atrium Therapeutics, Inc. (RNA) is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. The company's stock is listed on NasdaqGS, with a current price of 8.00 USD and a 1-year target estimate of 25.00 USD. Recent analyst coverage from Roth Capital initiated a "Buy" rating with a price target of 15.
Atrium Therapeutics, Inc. (RNA) stock price, news, quote and history
Atrium Therapeutics, Inc. (RNA) stock closed at $8.20, up 0.49%, on October 23. The company, which specializes in RNA therapeutics for cardiomyopathies, has seen significant year-to-date and annual declines in its stock performance. Analysts currently have an average price target of $23.00, with Roth Capital initiating coverage with a "Buy" rating and a $15 price target.
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics, Inc. announced inducement grants on October 20, 2026, under its 2026 Employment Inducement Incentive Award Plan. These grants were made to a newly hired non-executive individual as a material inducement for their employment. The awards include non-qualified stock options for 9,500 shares and restricted stock units for 4,750 shares, both vesting over several years subject to continued service.
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Yakira Capital Management, a shareholder of Atrium Therapeutics, is urging the company's Board of Directors to initiate a strategic review, reduce cash spending, and explain a recent dilutive equity financing. Yakira questions the decision to raise $50 million after shares fell significantly, arguing the valuation does not reflect the company's net cash, its collaboration with Bristol Myers Squibb, or its internal development pipeline. The firm believes a strategic review is necessary to maximize shareholder value before further cash burn and dilution occur.
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Yakira Capital Management, a shareholder of Atrium Therapeutics, has publicly urged the company's Board of Directors to initiate a strategic review, reduce cash spending, and provide a clear explanation for its recent dilutive $50 million private placement. Yakira argues that the financing, executed at a deeply depressed valuation after shares fell 44%, has eroded shareholder value and questions why alternatives like a rights offering were not considered. The firm emphasizes Atrium's substantial net cash, a valuable collaboration with Bristol Myers Squibb, and an internal development pipeline, asserting that the current market valuation significantly undervalues these assets.
Cantor Fitzgerald reiterates Atrium Therapeutics stock Overweight By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating and a $25.00 price target for Atrium Therapeutics (NASDAQ:RNA), following a $50 million private placement. This financing extends the company's cash runway through 2028 and has brought in institutional investors, which is seen as significant given Atrium's spinout from Avidity. Despite the stock trading at a negative enterprise value and near its 52-week low, Cantor Fitzgerald believes the market is undervaluing the company, expecting recognition of this disconnect before the first clinical readout next year.
Cantor Fitzgerald reiterates Atrium Therapeutics stock Overweight
Cantor Fitzgerald has reiterated an Overweight rating and a $25.00 price target for Atrium Therapeutics (NASDAQ:RNA) following a recent $50 million private placement. This financing is expected to extend the company's cash runway through 2028. The firm believes the market is significantly undervaluing Atrium Therapeutics, which currently trades at an approximate negative $120 million enterprise value, and sees the current period as an opportune time for investment.
Cantor Fitzgerald reiterates Atrium Therapeutics stock Overweight By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating and a $25.00 price target for Atrium Therapeutics (NASDAQ:RNA) following a $50 million private placement, which is expected to extend the company's cash runway through 2028. The firm highlighted that Atrium Therapeutics shares are significantly undervalued by the market, trading at an approximate negative $120 million enterprise value, and expects investors to recognize this value ahead of upcoming clinical readouts. InvestingPro analysis also supports the undervaluation, noting the company's strong cash position relative to debt.
Including spin-off equity awards, Atrium Therapeutics (RNA) corrects its post-offering count to 21.6M.
Atrium Therapeutics (RNA) has corrected its post-offering share count to 21.6 million common shares outstanding. This correction, detailed in an amended 8-K filing, includes shares issued as part of make-whole equity awards related to its spin-off from Avidity Biosciences. The company recently entered into a securities purchase agreement to sell over 5.1 million common shares and pre-funded warrants for an additional 1.1 million shares to accredited investors.
Press Release: Atrium Therapeutics Announces $50 Million Private Placement
Atrium Therapeutics has announced a private placement of its common stock and warrants, aiming to raise $50 million. The company plans to use the net proceeds from this financing to advance its clinical pipeline and for general corporate purposes. This strategic move is expected to bolster Atrium's financial position as it continues to develop its therapeutic candidates.
Atrium Therapeutics Announces $50 Million Private Placement
Atrium Therapeutics (Nasdaq: RNA) announced a private placement financing expected to generate $50 million in gross proceeds. The financing involves the sale of common stock and pre-funded warrants to institutional investors, including Sirenia Capital Management LP and Aberdeen Investments. Atrium intends to use the net proceeds, along with existing cash, to fund the development of its lead product candidates, other research programs, and general corporate purposes, extending its operations through 2028.
Atrium Therapeutics Secures $50 Million Private Placement to Advance RNA-Based Cardiology Pipeline
Atrium Therapeutics, Inc. (Nasdaq: RNA) has secured $50 million through a private placement with institutional investors, including Sirenia Capital Management and Casdin Capital. This funding will advance its pipeline of RNA-based therapies for genetically driven heart diseases, extending its operational runway through 2028. The company's lead candidate, ATR 1072 for PRKAG2 syndrome, recently received FDA clearance for a Phase 1/2 clinical trial, and Atrium is also developing ATR 1086 for PLN cardiomyopathy.
Atrium Therapeutics Secures Nearly $50 Million Through October 2026 PIPE Offering
Atrium Therapeutics announced a private placement offering of common stock and pre-funded warrants, aiming to raise approximately $50 million. The offering includes over 5 million shares of common stock and warrants for an additional 1.1 million shares, with the transaction expected to close around October 9, 2026. The funds will be used to advance product candidates, support research, and for general corporate purposes, extending the company's cash runway through 2028.
Atrium Therapeutics raises $50 million in private placement By Investing.com
Atrium Therapeutics, Inc. announced it has entered into a securities purchase agreement with institutional investors for a private placement expected to generate approximately $50 million in gross proceeds. The company plans to use the net proceeds to fund the development of its lead product candidates, other research programs, working capital, and general corporate purposes, extending its operational funding through 2028. The private placement involves issuing common stock and pre-funded warrants, priced at-the-market under Nasdaq rules, with Leerink Partners acting as lead placement agent.
Atrium Therapeutics Raises About $50 Million in PIPE at $7.93; Adds Pre-Funded Warrants
Atrium Therapeutics has announced a private investment in public equity (PIPE) expected to generate approximately $50 million. The company will sell shares at $7.93 each and pre-funded warrants at $7.929, with closing anticipated around October 9, 2026. The net proceeds will be used to advance its lead programs, other research, and general corporate needs.
Atrium Therapeutics Announces $50 Million Private Placement
Atrium Therapeutics (RNA) announced a private placement aiming to raise approximately $50 million in gross proceeds through the issuance of common shares and pre-funded warrants. The company expects these funds, combined with existing cash, to support its operations, including the development of two lead product candidates and other research programs, through 2028. The private placement is anticipated to close around October 9, 2026.
Atrium Therapeutics raises $50M in private placement
Atrium Therapeutics, a biopharmaceutical company focused on RNA therapeutics for cardiac conditions, announced a $50 million private placement. The financing includes common stock and pre-funded warrants, priced at-the-market under Nasdaq rules, and is expected to close around October 9, 2026. The funds will be used for product development, research programs, and general corporate purposes, extending operations through 2028.
Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com
This article reports on the Form 4 filing for Atrium Therapeutics Inc. on September 27. It is a brief financial news item from Investing.com, providing basic information about the regulatory filing.
Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com
The article reports on a Form 4 filing for Atrium Therapeutics Inc. on September 27. It also includes a stock market snapshot, commodity prices, bond yields, and trending stock information, but provides no further details on the Form 4 itself.
Atrium Therapeutics stock advances its RNA pipeline toward Phase I/ II
Atrium Therapeutics is advancing its RNA therapeutics pipeline, particularly its lead PRKAG2 program, towards a Phase I/II study with initial data expected in the second half of 2027. The company closed at USD 9.22 on Nasdaq and reported USD 30 million in milestone payments from a collaboration with Bristol Myers Squibb, which provides non-dilutive capital to fund operations through mid-2028. This funding supports the company's early clinical timetable as it moves from regulatory preparation to patient dosing.
RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas
Atrium Therapeutics Inc. (RNA) is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies, with lead candidates ATR 1072 and ATR 1086 addressing severe, life-threatening conditions. The company's stock is currently trading at $8.55 with a market capitalization of $141.81M, and it was founded on September 30, 2025. Recent news includes inducement grants under Nasdaq Listing Rule 5635(c)(4) and participation in upcoming investor conferences.
Tax withholding trims Atrium Therapeutics (RNA) director's stake
Atrium Therapeutics (RNA) director Sarah Boyce had 126,418 shares of common stock withheld on September 18, 2026, to cover tax obligations from restricted stock unit vesting. After this transaction, she directly holds 138,668 shares. The filing indicates this was a tax withholding, not a market sale, and no Rule 10b5-1 trading plan was involved.
2,375 Atrium Therapeutics (RNA) shares withheld for taxes
Atrium Therapeutics' Chief Corporate Affairs Officer, Stephanie Kenney, had 2,375 shares of common stock withheld on September 18, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. This disposition resulted in Kenney directly holding 33,085 shares of common stock, and the transaction was not made under a Rule 10b5-1 plan. The shares were valued at $8.95 each for tax purposes.
Director at Atrium Therapeutics (RNA) has 22,812 shares withheld for taxes
Atrium Therapeutics director Michael W. Flanagan reported a Form 4 reflecting the withholding of 22,812 shares of Common Stock on September 18, 2026. This action was taken to satisfy tax withholding obligations arising from the vesting of restricted stock units, and not as an open-market trade. Following this transaction, Flanagan directly holds 31,974 shares of Common Stock.
Form 4 Atrium Therapeutics Inc For: 22 September By Investing.com
This article announces the filing of a Form 4 for Atrium Therapeutics Inc. on September 22. It is a brief financial news update published by Investing.com. The content provided is minimal, primarily indicating the occurrence of the SEC filing.
Form 4 Atrium Therapeutics Inc For: 22 September By Investing.com
This article reports on a Form 4 filing for Atrium Therapeutics Inc., dated September 22. Form 4 is a document required by the SEC when there is a change in beneficial ownership of securities by a company's officers, directors, or 10% shareholders. The brief piece indicates that this financial disclosure is available through Investing.com.
One new hire gets 13,500 options and 6,750 stock units from Atrium Therapeutics
Atrium Therapeutics (RNA) granted equity inducement awards to a newly hired non-executive employee on September 20, 2026, under its 2026 Employment Inducement Incentive Award Plan. The employee received non-qualified stock options for 13,500 shares at an exercise price of $8.95 per share and restricted stock units for 6,750 shares, both with specific vesting schedules. These awards were approved by the Human Capital Management Committee of the board, in accordance with Nasdaq Listing Rule 5635(c)(4).
21K Atrium Therapeutics (RNA) shares withheld for CMO's taxes
Atrium Therapeutics' Chief Medical Officer, Steven George Hughes, had 21,459 shares withheld for tax obligations related to restricted stock unit vesting. This transaction, valued at $8.95 per share, reduced his direct holdings to 51,638 shares. The event was documented in a Form 4 SEC filing on September 22, 2026.
Tax withholding trims 11,632 Atrium Therapeutics (RNA) shares, not a market sale
Atrium Therapeutics (RNA) CEO, Kathleen P. Gallagher, had 11,632 shares of common stock withheld on September 18, 2026, to cover tax obligations related to vesting restricted stock units. This was not a market sale, and she continues to hold 119,729 shares. The withheld shares were valued at $8.95 each.